Key reason why some cancers do not respond to immunotherapy identified

Researchers identify SLC13A3 as a key player in tumor cell survival and immune therapy resistance, highlighting its potential as a target to improve cancer treatment outcomes. 

Study: Itaconate transporter SLC13A3 impairs tumor immunity via endowing ferroptosis resistance. Image Credit: Sebastian Kaulitzki/Shutterstock.com

Study: Itaconate transporter SLC13A3 impairs tumor immunity via endowing ferroptosis resistance. Image Credit: Sebastian Kaulitzki/Shutterstock.com

In a recent study published in Cancer Cell, a team led by scientists from the University of Michigan investigated the role of itaconate transporters in helping tumor cells escape ferroptosis and lowering the efficacy of immune checkpoint blockade (ICB) therapies.

The study examined how the itaconate transporter SLC13A3 modulated tumor immunity by activating the pathways involved in ferroptosis evasion and contributed to the development of resistance to immunotherapy.

Background

Ferroptosis is a regulated form of cell death that has emerged as an important process in cancer biology, especially because of its links to immune responses and treatment resistance. The use of ICB therapies aimed at boosting the body’s immune response against tumors has shown varying effectiveness across cancers.

One of the challenges in ICB therapies is the development of treatment resistance in tumors, which is possibly linked to their ability to avoid ferroptosis. Moreover, a key factor that influences ferroptosis resistance is the action of specific metabolic pathways that shield the tumor cells from the oxidative damage required to induce this regulated cell death.

Itaconate is a metabolite produced by immune cells in the tumor microenvironment and is believed to enhance tumor survival by preventing ferroptosis. However, exactly how tumors acquire itaconate and utilize it to resist cell death is not well understood.

About the study

In the present study, the scientists examined the role of itaconate transporters such as SLC13A3 in facilitating the uptake of itaconate into tumor cells and potentially enabling tumor cells to evade immune-mediated ferroptosis.

This study employed murine models and genetic cell lines to investigate the role of SLC13A3 in tumor immunity and ferroptosis resistance. The researchers treated cultured tumor cells with ferroptosis inducers such as Erastin, along with itaconate, to investigate ferroptosis sensitivity. The viability of the cells was assessed using flow cytometry. Furthermore, mice lacking SLC13A3 in tumor cells were used to explore immune response changes within the tumor microenvironments, which is essential for analyzing immune cell infiltration and activation.

The study also used clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9) technology to knock out SLC13A3 in specific cell lines, and Western blotting was performed to confirm successful knockouts.

Metabolomic assays were used to measure itaconate levels within tumor cells and in the surrounding interstitial fluid. Liquid chromatography-mass spectrometry (LC-MS) was performed to track the uptake of labeled itaconate in tumor cells with and without SLC13A3 expression. The study also included homology modeling and molecular docking analyses to identify potential competitive ligands of SLC13A3.

Results

The study found that the expression of the itaconate transporter SLC13A3 in tumor cells was associated with resistance to ferroptosis, which ultimately impaired immune-mediated tumor suppression.

The results showed that SLC13A3 was involved in importing itaconate into the tumor cells, which activated an antioxidant pathway mediated by nuclear factor erythroid 2-related factor 2 (NRF2) and solute carrier family 7 member 11 (SLC7A11). The activation of the antioxidant pathway protected the tumor cells from oxidative damage and allowed them to evade ferroptosis.

The researchers also found that in several tumor models, high levels of SLC13A3 correlated with poor response to ICB therapy. Furthermore, patients with increased SLC13A3 expression in their tumor cells had shorter overall survival, which highlighted the role of SLC13A3 in limiting the effectiveness of immunotherapy.

The knockout experiments using mouse models also found that the inactivation of SLC13A3 in cancer cells led to enhanced immune cell infiltration and improved tumor control, while the presence of SLC13A3 lowered the immune activity within the tumor microenvironment.

Furthermore, blocking SLC13A3 with specific inhibitors improved ferroptosis sensitivity in tumor cells, both alone and in combination with ICB treatments. The researchers reported that this was achieved by reversing the itaconate-induced ferroptosis resistance, which led to improved T-cell responses and enhanced tumor suppression in the murine models.

Conclusions

Overall, the findings indicated that targeting the itaconate transporter SLC13A3 may offer a promising therapeutic strategy to prevent the development of tumor resistance to ferroptosis and enhance the efficacy of immunotherapy. By inhibiting this transporter, tumors could become more susceptible to oxidative damage and immune responses, potentially improving the outcomes of cancer treatments that rely on ferroptosis induction.

Journal reference:
  • Lin, H., Tison, K., Du, Y., Kirchhoff, P., Kim, C., Wang, W., Yang, H., Pitter, M., Yu, J., Liao, P., Zhou, J., Vatan, L., Grove, S., Wei, S., Vigil, T., Shah, Y. M., Mortensen, R., Kryczek, I., Garmire, L., & Sivaccumar, Jwala P. (2024). Itaconate transporter SLC13A3 impairs tumor immunity via endowing ferroptosis resistance. Cancer Cell. doi:10.1016/j.ccell.2024.10.010 https://www.sciencedirect.com/science/article/pii/S1535610824003982 
Dr. Chinta Sidharthan

Written by

Dr. Chinta Sidharthan

Chinta Sidharthan is a writer based in Bangalore, India. Her academic background is in evolutionary biology and genetics, and she has extensive experience in scientific research, teaching, science writing, and herpetology. Chinta holds a Ph.D. in evolutionary biology from the Indian Institute of Science and is passionate about science education, writing, animals, wildlife, and conservation. For her doctoral research, she explored the origins and diversification of blindsnakes in India, as a part of which she did extensive fieldwork in the jungles of southern India. She has received the Canadian Governor General’s bronze medal and Bangalore University gold medal for academic excellence and published her research in high-impact journals.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Sidharthan, Chinta. (2024, November 12). Key reason why some cancers do not respond to immunotherapy identified. News-Medical. Retrieved on November 13, 2024 from https://www.news-medical.net/news/20241112/Key-reason-why-some-cancers-do-not-respond-to-immunotherapy-identified.aspx.

  • MLA

    Sidharthan, Chinta. "Key reason why some cancers do not respond to immunotherapy identified". News-Medical. 13 November 2024. <https://www.news-medical.net/news/20241112/Key-reason-why-some-cancers-do-not-respond-to-immunotherapy-identified.aspx>.

  • Chicago

    Sidharthan, Chinta. "Key reason why some cancers do not respond to immunotherapy identified". News-Medical. https://www.news-medical.net/news/20241112/Key-reason-why-some-cancers-do-not-respond-to-immunotherapy-identified.aspx. (accessed November 13, 2024).

  • Harvard

    Sidharthan, Chinta. 2024. Key reason why some cancers do not respond to immunotherapy identified. News-Medical, viewed 13 November 2024, https://www.news-medical.net/news/20241112/Key-reason-why-some-cancers-do-not-respond-to-immunotherapy-identified.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Overtreatment of older men with prostate cancer raises concerns